SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the pricing of its upsized initial public offering of 23,333,334 shares of common stock at a price to the public of $15.00 per share.

加利福尼亚州南旧金山，2026年9月17日（环球电讯社）——专注于开创用于治疗免疫介导疾病和癌症的新一代精准药物的后期临床阶段生物制药公司Electra Therapeutics, Inc.今日宣布其扩大规模的首次公开募股定价，以每股15.00美元的公开发行价格发行23,333,334股普通股。

The gross proceeds to Electra from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Electra, are expected to be approximately $350.0 million. In addition, Electra has granted the underwriters a 30-day option to purchase up to an additional 3,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

在扣除由 Electra 支付的承销折扣、佣金及预估发行费用之前，Electra 从本次发行中获得的总收益预计约为 3.5 亿美元。此外，Electra 已授予承销商一项为期 30 天的选择权，可按公开发行价格减去承销折扣和佣金的价格，额外购买最多 3,500,000 股普通股。

All of the shares of common stock are being offered by Electra..

所有普通股股份均由 Electra 提供。

The shares are expected to begin trading on The Nasdaq Global Select Market on September 18, 2026, under the ticker symbol “ETRA.” The offering is expected to close on September 21, 2026, subject to the satisfaction of customary closing conditions.

预计该股票将于2026年9月18日在纳斯达克全球精选市场开始交易，股票代码为“ETRA”。在满足惯常交割条件的前提下，预计本次发行将于2026年9月21日完成交割。

Jefferies, TD Cowen, Evercore ISI and Cantor are acting as joint book-running managers for the offering.

杰富瑞、TD Cowen、Evercore ISI 和坎托担任此次发行的联合账簿管理人。

Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on September 17, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities.

与这些证券相关的注册声明已提交至美国证券交易委员会（SEC），并于2026年9月17日生效。注册声明的副本可通过SEC网站www.sec.gov获取。本次发售仅通过构成与这些证券相关注册声明一部分的招股说明书进行。

When available, copies of the final prospectus relating to the initial public offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Evercore Group L.L.C., 55 East 52nd Street, 35th Floor, New York, New York 10055, Attention: Equity Capital Markets, or by email at ecm.prospectus@evercore.com or by telephone at (888) 474-0200; or Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.

如有提供，与首次公开发行相关的最终招股说明书副本可从以下机构获取：Jefferies LLC，收件人：股票承销团招股说明书部门，地址：520 Madison Avenue, New York, New York 10022，电话：(877) 821-7388，电子邮件：Prospectus_Department@Jefferies.com；TD Securities (USA) LLC，转交 Broadridge Financial Solutions，地址：1155 Long Island Avenue, Edgewood, NY 11717，电子邮件：TDManualrequest@broadridge.com；Evercore Group L.L.C.，地址：55 East 52nd Street, 35th Floor, New York, New York 10055，收件人：股权资本市场部，电子邮件：ecm.prospectus@evercore.com，电话：(888) 474-0200；或 Cantor Fitzgerald & Co.，收件人：股权资本市场部，地址：110 East 59th Street, 6th Floor, New York, New York 10022，电子邮件：prospectus@cantor.com。

.

。

This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售要约，也不构成购买这些证券的要约邀请；在任何州或司法管辖区，若在此类证券根据该州或司法管辖区的证券法进行注册或资格认定之前，此类要约、邀请或销售行为属违法，则不得在该州或司法管辖区销售这些证券。

Any offers, solicitations of offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended..

任何要约、购买要约的征求或任何证券的销售，都将根据经修订的《1933年证券法》的注册要求进行。

About Electra Therapeutics

关于 Electra Therapeutics

Electra Therapeutics is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company’s novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations and increases upon activation, to enable selective depletion of disease-driving cells while preserving normal immune function.

Electra Therapeutics 是一家处于临床后期阶段的生物制药公司，专注于开创一类新型精准药物，用于治疗免疫介导性疾病和癌症。该公司的创新方法靶向信号调节蛋白（SIRP），这是一类细胞表面受体家族，其表达仅限于特定的免疫细胞群，并在激活时上调，从而能够在保留正常免疫功能的同时，选择性清除致病细胞。

The company’s lead product candidate, ipsoprubart (ELA026), is a novel pan-SIRP monoclonal antibody currently in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory syndrome for which there are no broadly approved therapies and survival has remained consistently poor over the past two decades.

公司的领先候选产品ipsoprubart（ELA026）是一种新型泛SIRP单克隆抗体，目前正在进行全球注册性临床试验，用于治疗继发性噬血细胞性淋巴组织细胞增生症（sHLH）。这是一种严重的过度炎症综合征，目前尚无广泛批准的治疗方法，且在过去二十年中患者的生存率一直较低。

Ipsoprubart is also being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory T-cell and natural-killer cell malignancies. ELA822, the company’s second clinical-stage product candidate, is a novel SIRPγ-specific antibody being developed for a broad range of chronic T cell-mediated immune and inflammatory diseases..

Ipsoprubart 也在针对复发/难治性 T 细胞和自然杀伤细胞恶性肿瘤患者的一项 I 期临床试验中进行评估。ELA822 是该公司的第二款处于临床阶段的候选产品，是一种新型 SIRPγ 特异性抗体，正在开发用于治疗多种慢性 T 细胞介导的免疫和炎症性疾病。

Contacts:

联系人：

Investor Contact:

投资者联系：

Monique Allaire, THRUST

莫妮克·阿莱尔，THRUST

monique@thrustsc.com

monique@thrustsc.com

Media Contact:

媒体联系人：

Sara Sutton, THRUST

萨拉·萨顿，THRUST

sarah@thrustsc.com

sarah@thrustsc.com